<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01815502</url>
  </required_header>
  <id_info>
    <org_study_id>PVL Fontan</org_study_id>
    <secondary_id>AHA</secondary_id>
    <nct_id>NCT01815502</nct_id>
  </id_info>
  <brief_title>Study of Effects of Sildenafil on Patients With Fontan Heart Circulation</brief_title>
  <official_title>Response to Sildenafil in Patients With Fontan Physiology, A Pressure-volume Loop Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will investigate the cardiovascular effects of sildenafil on patients with Fontan
      circulation. Recent studies suggest that sildenafil may improve exercise in patients with
      Fontan circulation. However, why this occurs is not known. The study will used specialized
      catheters to measure pressure and volume. The measure of pressure and volume leads to more
      detailed analysis of heart function. Patients will receive either sugar pill or sildenafil
      prior to catheterization. It is believed that sildenafil will improve relaxation and
      contraction of the heart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Modifications to surgical procedures and medical treatment have led to a rapidly declining
      mortality rates in patients with single-ventricle heart disease (SV). However, SV patients
      still suffer from lower quality of life, decreased exercise capacity, worse
      neurodevelopmental outcomes and many other morbidities. While patients with SV circulation
      only make a small portion of all congenital heart diseases, 2-4 %, they require a great deal
      of resource utilization.

      Standard medical treatments for adult heart failure have not had the same success in the SV
      population. Phosphodiesterase 5 (PDE5) inhibitors have recently become a frequently used
      medication class in patients with SV heart disease to treat pulmonary hypertension, heart
      failure, as well as &quot;Fontan&quot; failure (i.e., plastic bronchitis and protein-losing
      enteropathy). While there have been findings of improved measures of exercise capacity and
      some reports of improved symptoms of heart failure, the physiologic mechanisms behind these
      findings are not completely understood. There have been reports, indicating that the
      phosphodiesterase five inhibitors improve ventricular function in biventricular circulation
      patients and animal models. The aim of our study was to investigate the effect of acute PDE5
      inhibition on ventricular function in SV patients after the final palliative surgery, the
      Fontan procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End-systolic Elastance</measure>
    <time_frame>10 minutes after imitation of dobutamine</time_frame>
    <description>end-systolic elastance (often abbreviated Ees or ESPVR) is a measure of contractility (systolic function)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>End-diastolic Pressure Volume Relationship</measure>
    <time_frame>10 minutes after imitation of dobutamine</time_frame>
    <description>End-diastolic pressure volume relationship (EDPVR) is a measure of diastolic (relaxation) heart function</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ventricular-arterial Coupling</measure>
    <time_frame>10 minutes after imitation of dobutamine</time_frame>
    <description>Ventricular-arterial coupling is a measure of efficiency of ventricular work in response to the work created by the vascular tree</description>
  </other_outcome>
  <other_outcome>
    <measure>Preload Augmentation</measure>
    <time_frame>10 minutes after imitation of dobutamine</time_frame>
    <description>Preload augmentation is a measure of how quickly the heart fills with blood during exercise</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Single Ventricle Heart Disease After Fontan Surgery</condition>
  <arm_group>
    <arm_group_label>Dobutamine + Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil will be given an one time dose 30 to 90 minutes prior to cardiac catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dobutamine + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to cardiac catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac catheterization</intervention_name>
    <description>All patients will receive a dobutamine infusion during catheterization. Patients were 1:1 randomized to a single dose of 1 mg/kg of sildenafil (max dose of 20 mg) or placebo 30-90 min prior to beginning of catheterization.</description>
    <arm_group_label>Dobutamine + Sildenafil</arm_group_label>
    <arm_group_label>Dobutamine + placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of a congenital heart defect that leads to single ventricle physiology

          -  Previously performed Fontan surgery

        Exclusion Criteria:

          -  The use of phosphodiesterase type 5 (PDE5) inhibitors at the time of catheterization
             of within 1 month of catheterization

               -  Unstable arrhythmia at the time of catheterization

               -  History of unstable arrhythmia within 2 months of catheterization

               -  Venous, arterial or cardiac malformation that precludes the proper placement of a
                  microconductance catheter

               -  Allergy to sildenafil or previous significant adverse reaction to sildenafil
                  (e.g. hypotension)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Butts, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew M Atz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Goldberg DJ, French B, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM, Rychik J. Impact of oral sildenafil on exercise performance in children and young adults after the fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011 Mar 22;123(11):1185-93. doi: 10.1161/CIRCULATIONAHA.110.981746. Epub 2011 Mar 7.</citation>
    <PMID>21382896</PMID>
  </reference>
  <reference>
    <citation>Goldberg DJ, French B, Szwast AL, McBride MG, Marino BS, Mirarchi N, Hanna BD, Wernovsky G, Paridon SM, Rychik J. Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation. Pediatr Cardiol. 2012 Jun;33(5):689-96. doi: 10.1007/s00246-012-0196-9. Epub 2012 Feb 14.</citation>
    <PMID>22331056</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>March 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2013</study_first_posted>
  <results_first_submitted>July 12, 2018</results_first_submitted>
  <results_first_submitted_qc>November 9, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">December 7, 2018</results_first_posted>
  <last_update_submitted>November 9, 2018</last_update_submitted>
  <last_update_submitted_qc>November 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Single ventricle</keyword>
  <keyword>Fontan</keyword>
  <keyword>Sildenafil</keyword>
  <keyword>Pressure-Volume Loops</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sildenafil</title>
          <description>Sildenafil will be given an one time dose 30 to 90 minutes prior to catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Dobutamine: Patients will receive a dobutamine infusion during catheterization.</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Dobutamine: Patients will receive a dobutamine infusion during catheterization.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sildenafil</title>
          <description>Sildenafil will be given an one time dose 30 to 90 minutes prior to catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Dobutamine: Patients will receive a dobutamine infusion during catheterization.</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Dobutamine: Patients will receive a dobutamine infusion during catheterization.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="6" upper_limit="17"/>
                    <measurement group_id="B2" value="8" lower_limit="5" upper_limit="15"/>
                    <measurement group_id="B3" value="8" lower_limit="5" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>End-systolic Elastance</title>
        <description>end-systolic elastance (often abbreviated Ees or ESPVR) is a measure of contractility (systolic function)</description>
        <time_frame>10 minutes after imitation of dobutamine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil will be given an one time dose 30 to 90 minutes prior to catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Dobutamine: Patients will receive a dobutamine infusion during catheterization.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes.
Dobutamine: Patients will receive a dobutamine infusion during catheterization.</description>
          </group>
        </group_list>
        <measure>
          <title>End-systolic Elastance</title>
          <description>end-systolic elastance (often abbreviated Ees or ESPVR) is a measure of contractility (systolic function)</description>
          <units>Ees in mmHg/ml/m2</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" lower_limit="0.01" upper_limit="1.5"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.74" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>End-diastolic Pressure Volume Relationship</title>
        <description>End-diastolic pressure volume relationship (EDPVR) is a measure of diastolic (relaxation) heart function</description>
        <time_frame>10 minutes after imitation of dobutamine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil will be given an one time dose 30 to 90 minutes prior to catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Dobutamine: Patients will receive a dobutamine infusion during catheterization.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Dobutamine: Patients will receive a dobutamine infusion during catheterization.</description>
          </group>
        </group_list>
        <measure>
          <title>End-diastolic Pressure Volume Relationship</title>
          <description>End-diastolic pressure volume relationship (EDPVR) is a measure of diastolic (relaxation) heart function</description>
          <units>mmHg/ms</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="499" lower_limit="367" upper_limit="899"/>
                    <measurement group_id="O2" value="953" lower_limit="654" upper_limit="1482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ventricular-arterial Coupling</title>
        <description>Ventricular-arterial coupling is a measure of efficiency of ventricular work in response to the work created by the vascular tree</description>
        <time_frame>10 minutes after imitation of dobutamine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dobutamine + Sildenafil</title>
            <description>Sildenafil will be given an one time dose 30 to 90 minutes prior to cardiac catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Cardiac catheterization: All patients will receive a dobutamine infusion during catheterization. Patients were 1:1 randomized to a single dose of 1 mg/kg of sildenafil (max dose of 20 mg) or placebo 30–90 min prior to beginning of catheterization.</description>
          </group>
          <group group_id="O2">
            <title>Dobutamine + Placebo</title>
            <description>Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to cardiac catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Cardiac catheterization: All patients will receive a dobutamine infusion during catheterization. Patients were 1:1 randomized to a single dose of 1 mg/kg of sildenafil (max dose of 20 mg) or placebo 30–90 min prior to beginning of catheterization.</description>
          </group>
        </group_list>
        <measure>
          <title>Ventricular-arterial Coupling</title>
          <description>Ventricular-arterial coupling is a measure of efficiency of ventricular work in response to the work created by the vascular tree</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.39" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.86" lower_limit="0.26" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Preload Augmentation</title>
        <description>Preload augmentation is a measure of how quickly the heart fills with blood during exercise</description>
        <time_frame>10 minutes after imitation of dobutamine</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil will be given an one time dose 30 to 90 minutes prior to catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Dobutamine: Patients will receive a dobutamine infusion during catheterization.</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Dobutamine: Patients will receive a dobutamine infusion during catheterization.</description>
          </group>
        </group_list>
        <measure>
          <title>Preload Augmentation</title>
          <description>Preload augmentation is a measure of how quickly the heart fills with blood during exercise</description>
          <units>ml/m^2</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" lower_limit="0.01" upper_limit="0.08"/>
                    <measurement group_id="O2" value="0.08" lower_limit="0.06" upper_limit="0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sildenafil</title>
          <description>Sildenafil will be given an one time dose 30 to 90 minutes prior to catheterization. Sildenafil will be given at a dose 1 milligram per kilogram with a maximum of 20 milligrams. During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Dobutamine: Patients will receive a dobutamine infusion during catheterization.</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Patients will be given a one time dose of sugar pill 30 to 90 minutes prior to catheterization.During the catheterization patients will have specialized catheter placed in the heart that measures pressure and volume simultaneously. The patients will undergo an infusion of dobutamine up to 10 micrograms per kilogram per minute to mimic exercise for up to ten minutes..
Dobutamine: Patients will receive a dobutamine infusion during catheterization.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrew M Atz</name_or_title>
      <organization>MUSC</organization>
      <phone>843-876-1698</phone>
      <email>atzam@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

